CARISMA THERAP (CARM)
(Delayed Data from NSDQ)
$1.41 USD
0.00 (0.00%)
Updated May 20, 2024 04:00 PM ET
After-Market: $1.40 -0.01 (-0.71%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CARM 1.41 0.00(0.00%)
Will CARM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CARM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CARM
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CARM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now
Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know
Other News for CARM
The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
Buy Rating Affirmed for Carisma Therapeutics Amid Progress in CAR-Monocyte Cancer Therapy
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Carisma Therapeutics: First patient dosed in Phase 1 clinical trial of CT-0525
Analysts Offer Insights on Healthcare Companies: Applied Therapeutics (APLT), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)